Innovations in molecular diagnostics leading to automation of instruments are resulting in expanded applications of molecular assay beyond just identification purposes. The automated molecular assays having reduced handling errors and enhanced limits of detection and quantitation are leading to the usage of molecular assays in therapeutic monitoring and drug prescription selection with an objective of avoiding toxicity and other side effects. The shift in paradigm of clinical laboratory testing and medicine have led to improved pharmacogenomics and patient stratification. Innovations in the novel detection of pathogens and microRNAs are contributing to the continued expansion of the market by changing the landscape of personalized care. Advancements in automated molecular assays are resulting in the elimination of discriminatory testing necessities for patients.
Modernized assays with improved efficacy are increasingly adopted all over the world, as these assays offer certain advantages such as data reliability, increased speed, ability of performing multiple assays at a time, which is resulting in reduced cost and high level of precision. Modification in the assays by medical laboratories for identification of rare diseases, innovations in the next generation molecular assays having cutting-edge technologies such as single molecule counting, improved automation in the molecular assays targeting drug efficacy issues such as antibiotic resistance detection, etc., are driving the global automated molecular assay market. However, issues related to the manufacturing stability of assays and detection of degenerated proteins are resulting in reduced clinical utility of automated molecular assay, which in turn are restraining the market.
The global automated molecular assay market can be segmented in terms of technique, testing type, application, end-user, and region. Based on technique, the market can be segmented into polymerase chain reaction (PCR), Enzyme-Linked Immuno-Sorbent Assay (ELISA), microarrays, lab-on-chip assays, gene expression profiling assays, and other biochemical assays. In terms of testing type, the market can be segmented into blood screening, virus screening, genetic material testing, oncological testing, and STD testing. The virus screening segment can be further sub-segmented into HPV testing, HIV testing, influenza testing, HCV testing, and others. Based on application, the market can be segmented into infection detection, blood donor screening, genomic profiling, molecular biomarker analysis, and others. In terms of end-user, the market can be segmented into hospitals, academic and research institutes, biopharmaceutical companies, and others.
Based on region, the Automated Molecular Assay market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to dominate the global market during the forecast period due to strong distribution networks of major market players, advances in molecular diagnostics leading to early detection of metabolites, proteins, DNA or RNA, and availability of skilled workforce to handle the instrumentation of automated assay. Asia Pacific is likely to witness an exponential growth during the forecast period, due to improvements in healthcare infrastructure, increasing number of regional manufacturers offering affordable yet technologically advanced products, and rising investments in research and development for innovations in the screening methodologies.
Development of proper reimbursement policies serve as a major opportunity for the global market. Multiple pathogen detection assays through advancements in the in-vitro detection techniques including genomics and proteomics are a growing trend in the global automated molecular assay market. Innovations in automated molecular assays include the ability to detect new variants of viruses, modifications in the genome of pathogens, and others. New product launches in the global market are primarily focused on detection of novel oncologic biomarkers, so as to allow the early detection of cancer.
Key players operating in the global automated molecular assay market include F. Hoffmann-La Roche Ltd, Luminex Corporation, Molecular Devices, LLC, Becton, Dickinson and Company, Siemens Healthcare GmbH, Tecan Trading AG, Agilent Technologies Inc., Thermo Fisher Scientific Inc., Invivoscribe, and Myriad Genetics, Inc. among others.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.